ICH E6 (R3) Is Reshaping Clinical Trials. Here’s What Sponsors, CROs, and Research Sites Need to Know

For years, clinical trial organizations have talked about modernization.

Risk-based oversight. Decentralized trials. Better quality systems. Improved transparency. Smarter operational controls.

Now, with the release of ICH E6 (R3), many of those conversations are no longer optional “future state” discussions. They are becoming regulatory expectations.

At myLaminin we’ve written extensively throughout our Clinical Trials Series about where the industry is heading and honestly, none of this should come as a surprise to sponsors, CROs, or research organizations paying attention to the direction clinical research has been moving over the past several years.

What ICH E6 (R3) really does is formalize a shift that was already happening; clinical trials are expected to be more proactive, more connected, more risk-aware, and far more operationally accountable than before.

And that affects everyone.

This Is Not Just Another Guideline Update

The International Council for Harmonisation didn’t release ICH E6 (R3) to create more paperwork. The update reflects the reality of modern clinical research.

Today’s trials are more complex than they were even five years ago:

• multiple vendors

• remote and hybrid study models

• digital systems everywhere

• growing data volumes

• global oversight requirements

• increasing pressure around patient safety and data integrity

The old model of managing studies through disconnected spreadsheets, siloed departments, and reactive quality processes simply does not hold up anymore. Regulators know it. Sponsors know it. CROs definitely know it.

And now the expectations are being written directly into the framework governing global Good Clinical Practice.

The Industry Has Been Moving Toward This for a While

A lot of the topics we’ve covered in our Clinical Trials Series already point directly to where ICH E6 (R3) is taking the industry. Whether it’s:

• inspection readiness

• operational oversight

• decentralized clinical trials

• data governance

• quality management

• vendor accountability

• documentation controls

• patient-centric trial models

The common theme has always been the same:

• Clinical trial operations can no longer function effectively in fragmented environments.

• Modern research requires visibility.

• It requires traceability.

• It requires organizations to identify issues earlier, before they become protocol deviations, audit findings, compliance failures, or patient safety concerns.

That’s really the heart of ICH E6 (R3).

Risk-Based Quality Management Is No Longer a “Nice to Have”

One of the biggest shifts in the updated guideline is the emphasis on proactive risk management. Not reactive, but proactive.

Organizations are now expected to actively identify:

• operational risks

• critical-to-quality factors

• oversight gaps

• data vulnerabilities

• vendor risks

• process weaknesses

And, they’re expected to do it continuously throughout the study lifecycle. That’s a major operational change for many organizations.

Historically, quality often sat in a separate lane from operations. But under ICH E6 (R3), quality management becomes part of everyday trial execution.

Clinical operations teams, QA, regulatory, data management, sponsors, vendors, everybody becomes part of the oversight ecosystem.

Decentralized Trials Added Flexibility and Complexity

The rise of decentralized and hybrid trials has absolutely improved accessibility for many patients. But it has also introduced entirely new layers of operational and compliance risk. Now organizations have to think about:

• remote oversight

• digital consent workflows and identity verification

• home health providers

• third-party technology vendors

• cybersecurity

• cross-border data handling

• real-time data visibility

That’s a lot to manage. ICH E6 (R3) acknowledges that modern clinical trials don’t always happen inside the clinic walls anymore. But it also makes clear that the same standards for quality, safety, and data integrity still apply, regardless of how decentralized the study becomes.

Data Integrity Is Becoming Operational, Not Just Technical

One thing becoming increasingly obvious across the industry is that data integrity is no longer just an IT conversation. It’s operational.

If systems don’t communicate properly, risk increases. If oversight is fragmented, risk increases. If documentation is difficult to track, risk increases.

And when organizations rely too heavily on manual processes, email chains, spreadsheets, and disconnected systems, visibility starts to break down fast.

ICH E6 (R3) pushes organizations toward stronger governance and better operational control, not just more technology for the sake of technology. That distinction matters.

Continuous Inspection Readiness Is the New Reality

For a long time, many organizations treated inspection readiness as something you prepared for when an audit was approaching. That mindset is changing quickly.

Under ICH E6 (R3), regulators increasingly expect organizations to demonstrate ongoing oversight and continuous control, not temporary cleanup before an inspection. That means:

• documentation needs to stay organized

• decisions need to be traceable

• issues need to be managed consistently

• oversight needs to be visible

• accountability needs to be clear

In practical terms, organizations need systems and processes that support readiness every day, not just during inspection season.

Technology Alone Will Not Solve This

One mistake the industry sometimes makes is assuming modernization simply means adding more software. It doesn’t.

Technology absolutely plays a role. But successful clinical trial oversight still depends heavily on:

• process design

• governance

• operational discipline

• communication

• accountability

• training

• cross-functional alignment

The organizations that adapt best to ICH E6 (R3) will likely be the ones that balance strong operational structure with practical usability for the people actually running studies every day.

Because at the end of the day, clinical trials are still run by people.

Where the Industry Goes From Here

ICH E6 (R3) is not just another compliance update sitting in a PDF somewhere. It represents a broader shift in how regulators expect clinical trials to operate moving forward. And realistically, this is only the beginning.

• More transparency.

• More accountability

• More proactive oversight.

• Better integration between quality and operations.

• Stronger control over risk.

The clinical research industry is continuing to evolve rapidly, especially as decentralized models, digital systems, and global trial structures become more common.

Organizations that start strengthening their operational foundations now will be in a much stronger position than those waiting until regulators force the issue later.

In short, the regulations are now pushing more accountability onto sponsors to ensure they are establishing Risk-Based Quality Management (RBQM). This essentially entails the following for all trials:

• Identification of Critical-to-Quality elements that must be tracked,

• Setting of Quality Tolerance Limits (QTLs) for each, and

• Setting Notifications/Alerts when these QTLs are breached.

Ensuring that vendors supporting these new protocols provide a ‘System Validation Package’ demonstrating how all this is supported.

This is essentially what the FDA is also looking to do to accelerate clinical trials and compress the gaps between phases, what they are calling “Real-Time Clinical Trials (RTCTs)”. The FDA recently put out an RFI (request for information) which you can find here.

The myLaminin Clinical Trials Management System (CTMS) module supports all of this out-of-the-box. myLaminin is unique because it integrates tightly with a robust data collection module that has strong reporting capabilities. It also supports accelerated clinical trial protocol setup, participant tracking, eTMF, PI review and 21 CFR Part 11 e-Signature, team training and certification tracking and Delegation Log. 

If you’re still using REDCap for data collection, you’re likely struggle to meet these new requirements effectively.

At myLaminin, our Clinical Trials Series continues to explore the operational, regulatory, and technological changes reshaping clinical research across Canada, the United States, Europe, the UK, and Australia.

Because this industry is changing fast, the organizations that adapt early will be the ones best positioned for long-term success.

__________________________________

Deanne Bassili (article author) is the COO of myLaminin, a secure research data administration and research data management platform for academia using blockchain and web3 technologies to secure sensitive research data and reduce operational inefficiencies for principal investigators, their team members, external collaborators, research legal services, research ethics boards, research librarians, IT, and administrators.